Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.

Samuel Dagogo-JackRobert FrederichJie LiuChristopher P CannonHarry ShiDavid Z I CherneyFrancesco CosentinoUrszula MasiukiewiczIra GantzRichard E Pratley

Published in: The Journal of clinical endocrinology and metabolism (2023)

In VERTIS CV patients, ertugliflozin reduced the likelihood of insulin initiation, delayed the time to insulin initiation by up to ∼1.8 years, and reduced insulin dose requirements vs placebo, without increasing hypoglycemia events.

Keyphrases

type diabetes
glycemic control
end stage renal disease

newly diagnosed
ejection fraction
prognostic factors

peritoneal dialysis
metabolic syndrome
insulin resistance

double blind
phase iii